4.6 Article

Hepatitis C Virus Controls Interferon Production through PKR Activation

期刊

PLOS ONE
卷 5, 期 5, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0010575

关键词

-

资金

  1. Institut Pasteur (IP)
  2. CNRS [URA3015]
  3. Ministere de l'Education et de la Recherche fellowship

向作者/读者索取更多资源

Hepatitis C virus is a poor inducer of interferon (IFN), although its structured viral RNA can bind the RNA helicase RIG-I, and activate the IFN-induction pathway. Low IFN induction has been attributed to HCV NS3/4A protease-mediated cleavage of the mitochondria-adapter MAVS. Here, we have investigated the early events of IFN induction upon HCV infection, using the cell-cultured HCV JFH1 strain and the new HCV-permissive hepatoma-derived Huh7.25.CD81 cell subclone. These cells depend on ectopic expression of the RIG-I ubiquitinating enzyme TRIM25 to induce IFN through the RIG-I/MAVS pathway. We observed induction of IFN during the first 12 hrs of HCV infection, after which a decline occurred which was more abrupt at the protein than at the RNA level, revealing a novel HCV-mediated control of IFN induction at the level of translation. The cellular protein kinase PKR is an important regulator of translation, through the phosphorylation of its substrate the eIF2 alpha initiation factor. A comparison of the expression of luciferase placed under the control of an eIF2 alpha-dependent (IRESEMCV) or independent (IRESHCV) RNA showed a specific HCV-mediated inhibition of eIF2 alpha-dependent translation. We demonstrated that HCV infection triggers the phosphorylation of both PKR and eIF2 alpha at 12 and 15 hrs post-infection. PKR silencing, as well as treatment with PKR pharmacological inhibitors, restored IFN induction in JFH1-infected cells, at least until 18 hrs post-infection, at which time a decrease in IFN expression could be attributed to NS3/4A-mediated MAVS cleavage. Importantly, both PKR silencing and PKR inhibitors led to inhibition of HCV yields in cells that express functional RIG-I/MAVS. In conclusion, here we provide the first evidence that HCV uses PKR to restrain its ability to induce IFN through the RIG-I/MAVS pathway. This opens up new possibilities to assay PKR chemical inhibitors for their potential to boost innate immunity in HCV infection.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Plant Sciences

Molecular and physiological characterization of the monosaccharide transporters gene family in Medicago truncatula

Fotios Komaitis, Katerina Kalliampakou, Maria Botou, Marios Nikolaidis, Chrysanthi Kalloniati, Dimitrios Skliros, Baoguo Du, Heinz Rennenberg, Grigoris D. Amoutzias, Stathis Frillingos, Emmanouil Flemetakis

JOURNAL OF EXPERIMENTAL BOTANY (2020)

Editorial Material Virology

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?

Sebastien Nisole, Aure Saulnier, Anne Gatignol

VIROLOGIE (2020)

Article Biochemistry & Molecular Biology

A Novel Cis-Acting RNA Structural Element Embedded in the Core Coding Region of the Hepatitis C Virus Genome Directs Internal Translation Initiation of the Overlapping Core+1 ORF

Niki Vassilaki, Efseveia Frakolaki, Katerina I. Kalliampakou, Panagiotis Sakellariou, Ioly Kotta-Loizou, Ralf Bartenschlager, Penelope Mavromara

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Article Medicine, Research & Experimental

Efficacy, accumulation, and transcriptional profile of anti-HIV shRNAs expressed from human U6, 7SK, and H1 promoters

Ryan P. Goguen, Olivier Del Corpo, Camille M. G. Malard, Aicha Daher, Sergio P. Alpuche-Lazcano, Michelle J. Chen, Robert J. Scarborough, Anne Gatignol

Summary: The expression of short hairpin RNAs in cells has therapeutic potential for diseases like HIV, with different promoters leading to variable levels of shRNA and potency. Among the studied promoters, the U6 promoter is the most accurate in positioning the +1 start site for shRNA expression. Expression level is the main determinant of shRNA potency.

MOLECULAR THERAPY-NUCLEIC ACIDS (2021)

Article Multidisciplinary Sciences

Alteration of L-Dopa decarboxylase expression in SARS-CoV-2 infection and its association with the interferon-inducible ACE2 isoform

George Mpekoulis, Efseveia Frakolaki, Styliani Taka, Anastasios Ioannidis, Alice G. Vassiliou, Katerina Kalliampakou, Kostas Patas, Ioannis Karakasiliotis, Vassilis Aidinis, Stylianos Chatzipanagiotou, Emmanouil Angelakis, Dido Vassilacopoulou, Niki Vassilaki

Summary: In COVID-19 patients, there was a significant increase in the expression of L-Dopa decarboxylase (DDC) gene, while non-infected and influenza-infected individuals did not show the same. Short ACE2 (dACE2), ISG56, and EPO also showed significant increases in SARS-CoV-2 infected individuals.

PLOS ONE (2021)

Article Infectious Diseases

Profound downregulation of neural transcription factor Npas4 and Nr4a family in fetal mice neurons infected with Zika virus

Sergio P. Alpuche-Lazcano, James Salibaid, Vivian V. Costa, Gabriel H. Campolina-Silva, Fernanda M. Marim, Lucas S. Ribeiro, Volker Blank, Andrew J. Mouland, Mauro M. Teixeira, Anne Gatignol

Summary: Zika virus (ZIKV) infection results in dysregulation of neural transcription factors and downregulation of microRNAs, specifically miR-7013-5p, leading to neuronal dysfunction. This study highlights the importance of the RNA interference pathway in ZIKV-induced pathology.

PLOS NEGLECTED TROPICAL DISEASES (2021)

Article Virology

Association of Hepatitis C Virus Replication with the Catecholamine Biosynthetic Pathway

George Mpekoulis, Vassilina Tsopela, Georgios Panos, Vasileios Siozos, Katerina Kalliampakou, Efseveia Frakolaki, Constantinos D. Sideris, Alice G. Vassiliou, Diamantis C. Sideris, Dido Vassilacopoulou, Niki Vassilaki

Summary: The biosynthesis and uptake of catecholamines restrict HCV replication in hepatocytes, while HCV has developed ways to reduce catecholamine production. Additionally, the effect of catecholamines on HCV is strongly related with oxidative stress, and strategies that lower cytosolic catecholamine levels positively affect the virus.

VIRUSES-BASEL (2021)

Article Virology

Dengue Virus Replication Is Associated with Catecholamine Biosynthesis and Metabolism in Hepatocytes

George Mpekoulis, Vassilina Tsopela, Anna Chalari, Katerina Kalliampakou, Georgios Panos, Efseveia Frakolaki, Raphaela S. Milona, Diamantis C. Sideris, Dido Vassilacopoulou, Niki Vassilaki

Summary: This study reveals the association between catecholamine biosynthesis/metabolism and Dengue virus replication. The production and uptake of biogenic amines impede DV replication, while the virus reduces catecholamine biosynthesis, metabolism, and transport. Altering the expression of L-Dopa decarboxylase (DDC) enhances virus replication, suggesting a negative effect of DDC on DV. In addition, the study demonstrates that dopamine uptake, rather than dopamine signaling, is responsible for the negative effect on DV.

VIRUSES-BASEL (2022)

Article Pharmacology & Pharmacy

Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2

Hirofumi Ohashi, Takayuki Hishiki, Daisuke Akazawa, Kwang Su Kim, Joohyeon Woo, Kaho Shionoya, Kana Tsuchimoto, Shoya Iwanami, Saya Moriyama, Hitomi Kinoshita, Souichi Yamada, Yudai Kuroda, Tsukasa Yamamoto, Noriko Kishida, Shinji Watanabe, Hideki Hasegawa, Tadaki Suzuki, Ken Maeda, Shuetsu Fukushi, Yoshimasa Takahashi, Shingo Iwami, Koichi Watashi

Summary: The study quantified the intrinsic sensitivity of SARS-CoV-2 Omicron subvariants BA.2 and BA.1 to neutralizing antibodies and antiviral drugs compared with other variants. Results showed diverse sensitivities of these variants to antibodies and differences in drug responses.

ANTIVIRAL RESEARCH (2022)

Review Pharmacology & Pharmacy

The discovery and development of RNA-based therapies for treatment of HIV-1 infection

Michelle J. Chen, Anne Gatignol, Robert J. Scarborough

Summary: This review examines the development of RNA technologies for treating HIV-1 infections over the past three decades, assessing their efficacy and safety. RNA-based therapies have the potential to be long-term and effective treatments for inhibiting HIV-1 through gene therapy.

EXPERT OPINION ON DRUG DISCOVERY (2023)

Article Virology

Antiviral Activity of Micafungin and Its Derivatives against SARS-CoV-2 RNA Replication

Shogo Nakajima, Hirofumi Ohashi, Daisuke Akazawa, Shiho Torii, Rigel Suzuki, Takasuke Fukuhara, Koichi Watashi

Summary: Echinocandin antifungal drugs, including micafungin and its derivatives, showed potent antiviral activities against SARS-CoV-2 and its variants, as well as other viruses. The derivatives Mi-2 and Mi-5 exhibited stronger antiviral activity than micafungin, indicating their potential as antiviral agents. These compounds were found to inhibit intracellular virus replication and retained their activity against drug-resistant SARS-CoV-2 variants. This study provides valuable evidence for the development of antiviral drugs using micafungin derivatives.

VIRUSES-BASEL (2023)

Article Cell Biology

Significance of Catecholamine Biosynthetic/Metabolic Pathway in SARS-CoV-2 Infection and COVID-19 Severity

George Mpekoulis, Katerina I. Kalliampakou, Raphaela S. Milona, Despoina Lagou, Anastasios Ioannidis, Edison Jahaj, Christos T. Chasapis, Dionysis Kefallinos, Ioannis Karakasiliotis, Anastasia Kotanidou, Stylianos Chatzipanagiotou, Dido Vassilacopoulou, Alice G. Vassiliou, Emmanouil Angelakis, Niki Vassilaki

Summary: SARS-CoV-2 infection is associated with the expression of the dopamine biosynthetic enzyme L-Dopa decarboxylase (DDC). The expression of DDC is negatively correlated with SARS-CoV-2 RNA levels in mild/no symptom COVID-19 patients, but significantly reduced in severe/critical cases, suggesting its potential as a marker of COVID-19 severity.
Article Immunology

Potential Anti-Mpox Virus Activity of Atovaquone, Mefloquine, and Molnupiravir, and Their Potential Use as Treatments

Daisuke Akazawa, Hirofumi Ohashi, Takayuki Hishiki, Takeshi Morita, Shoya Iwanami, Kwang Su Kim, Yong Dam Jeong, Eun-Sil Park, Michiyo Kataoka, Kaho Shionoya, Junki Mifune, Kana Tsuchimoto, Shinjiro Ojima, Aa Haeruman Azam, Shogo Nakajima, Hyeongki Park, Tomoki Yoshikawa, Masayuki Shimojima, Kotaro Kiga, Shingo Iwami, Ken Maeda, Tadaki Suzuki, Hideki Ebihara, Yoshimasa Takahashi, Koichi Watashi

Summary: In a drug repurposing study, 132 approved drugs were screened using an MPXV infection cell system, and potential drug candidates were identified. Atovaquone was predicted to have clinical impact through mathematical modeling. This research suggests that Atovaquone could be a potential treatment candidate for mpox.

JOURNAL OF INFECTIOUS DISEASES (2023)

Article Oncology

Identification of Membrane-expressed CAPRIN-1 as a Novel and Universal Cancer Target, and Generation of a Therapeutic Anti-CAPRIN-1 Antibody TRK-950

Fumiyoshi Okano, Takanori Saito, Yoshitaka Minamida, Shinichi Kobayashi, Takayoshi Ido, Yasushi Miyauchi, Ukei Wasai, Daisuke Akazawa, Masahiko Kume, Masaki Ishibashi, Ke Jiang, Alexandra Aicher, Christopher Heeschen, Tetsu Yonehara

Summary: CAPRIN-1, expressed on the cell membrane surface, is a promising target for cancer treatment. It is present in highly tumorigenic cancer stem cells and metastatic cancer cells induced by epithelial-mesenchymal transition (EMT). A therapeutic humanized anti-CAPRIN-1 antibody (TRK-950) has been developed and shown to bind specifically to cancer cells and exhibit antitumor effects. Clinical studies of TRK-950, including a phase I study and a phase Ib study in combination with approved drugs, are underway.

CANCER RESEARCH COMMUNICATIONS (2023)

Meeting Abstract Biotechnology & Applied Microbiology

Identification of Top Anti-HIV-1 RNAs for Use in HIV-1 Gene Therapy

Robert J. Scarborough, Ryan P. Goguen, Camille M. G. Malard, Olivier Del Corpo, Michelle J. Chen, Aicha Daher, Anne Gatignol

MOLECULAR THERAPY (2020)

暂无数据